Skip to main content
. Author manuscript; available in PMC: 2012 Jul 1.
Published in final edited form as: Cancer Res. 2011 Apr 15;71(13):4585–4597. doi: 10.1158/0008-5472.CAN-11-0127

Figure 6.

Figure 6

The combination of trastuzumab and oxamate effectively inhibits tumor growth in vivo.

A, Pre-established BT474 (left) or BT474/TR (right) tumor xenografts were treated with Control (PBS), Ttzm (10mg/kg, i.p., 2×/wk × 3 wks), OX (750mg/kg, i.p., daily × 21 days), or a combination of the agents. Data are presented as the relative tumor size. Statistical analysis of the differences of average tumor sizes in the single treatment group and the combination group was performed using the unpaired Student's t test. *, P<0.05, **, P<0.01. B, Tumors derived from BT474 cells (left) or BT474/TR cells (right) were lysed for LDH activity assay. Data are presented as the percentage of LDH activity measured in the control group. C, LDH activity in tumors derived from BT474 or BT474/TR cells. Data are shown as a percentage relative to BT474 cells-formed tumors. Columns, mean of three independent tumors; bars, SE. *, P<0.05, ***, P<0.001.